Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate
Portfolio Pulse from Benzinga Newsdesk
Regulus Therapeutics (NASDAQ:RGLS) reported a Q2 EPS of $(0.17), missing the analyst consensus estimate of $(0.13) by 30.77%. This represents a 54.05% improvement over the $(0.37) loss per share from the same period last year.
August 08, 2024 | 9:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regulus Therapeutics reported a Q2 EPS of $(0.17), missing the analyst estimate of $(0.13) by 30.77%. Despite the miss, the loss per share improved by 54.05% from the same period last year.
The significant miss on EPS estimates is likely to negatively impact the stock price in the short term. However, the improvement in losses compared to the previous year may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100